Drug Approval | May 01, 2026
Dr Reddy’s becomes first to secure Health Canada nod for generic Semaglutide injection
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
The move reinforces Croda’s push to fuel growth through high-impact innovation across its Consumer Care portfolio
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
Subscribe To Our Newsletter & Stay Updated
